JY
PRQR icon

Jeff Yass’s ProQR Therapeutics PRQR Stock Holding History

Jeff Yass’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,206
Closed -$19.8K – 14285
2026
Q1 		$19.8K Buy
+12,206
New +$20K ﹤0.01% 12864
2025
Q4 		– Sell
-25,245
Closed -$59K – 13327
2025
Q3 		$53.8K Buy
+25,245
New +$55.2K ﹤0.01% 11840
2025
Q1 		– Sell
-67,054
Closed -$143K – 13243
2024
Q4 		$178K Buy
67,054
+24,831
+59% +$78.8K ﹤0.01% 10857
2024
Q3 		$76.8K Sell
42,223
-53,895
-56% -$101K ﹤0.01% 11190
2024
Q2 		$160K Sell
96,118
-44,033
-31% -$85.5K ﹤0.01% 10628
2024
Q1 		$318K Buy
140,151
+126,184
+903% +$270K ﹤0.01% 9582
2023
Q4 		$27.7K Sell
13,967
-26,643
-66% -$40.9K ﹤0.01% 11897
2023
Q3 		$52.8K Buy
+40,610
New +$63.9K ﹤0.01% 11279
2023
Q1 		– Sell
-164,821
Closed -$504K – 13280
2022
Q4 		$610K Buy
+164,821
New +$216K ﹤0.01% 7343
2022
Q3 		– Sell
-39,565
Closed -$31.8K – 13925
2022
Q2 		$31K Buy
+39,565
New +$29.5K ﹤0.01% 12206
2022
Q1 		– Sell
-38,609
Closed -$129K – 13771
2021
Q4 		$309K Sell
38,609
-89,657
-70% -$683K ﹤0.01% 10431
2021
Q3 		$1.07M Buy
128,266
+85,407
+199% +$558K ﹤0.01% 7371
2021
Q2 		$289K Sell
42,859
-21,399
-33% -$138K ﹤0.01% 10837
2021
Q1 		$425K Buy
+64,258
New +$328K ﹤0.01% 9853
2020
Q3 		– Sell
-11,501
Closed -$70K – 11017
2020
Q2 		$70K Sell
11,501
-1,257
-10% -$6.79K ﹤0.01% 9652
2020
Q1 		$70K Sell
12,758
-3,990
-24% -$30.6K ﹤0.01% 9519
2019
Q4 		$166K Buy
+16,748
New +$130K ﹤0.01% 8885
2018
Q2 		– Sell
-15,905
Closed -$49K – 10226
2018
Q1 		$49K Sell
15,905
-13,980
-47% -$45K ﹤0.01% 8956
2017
Q4 		$96K Buy
+29,885
New +$107K ﹤0.01% 8708

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Jeff Yass's PRQR Position: Q2 2026 in Review

Jeff Yass sold out of ProQR Therapeutics (PRQR) in Q2 2026, closing a stake of 12,206 shares — an estimated $19.8K sold.

Jeff Yass first reported a position in PRQR in Q4 2017 and held it in 19 quarters. The position peaked at $1.07M in Q3 2021. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Jeff Yass reported no remaining ProQR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 12,206 ProQR Therapeutics shares in Q2 2026, an estimated $19.8K.
  • Jeff Yass first reported a position in ProQR Therapeutics in Q4 2017 and held it in 19 quarters.
  • Jeff Yass's ProQR Therapeutics position peaked at $1.07M in Q3 2021.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.